Save-A-Lot looking for college interns to ‘hit the road’
ST. LOUIS — Save-A-Lot, a wholly owned subsidiary of Supervalu, on Monday launched a national search for a team of two interns to serve as brand ambassadors — or more aptly titled Road Scholars — for its 2012 Fuel Your Family Road Trip campaign.
The winning team will hit the road at the end of July for a four-week tour to 12 U.S. cities to personally bring the brand to consumers and help show people how Save-A-Lot can help families with savings of up to 40%, compared with traditional grocery stores.
Throughout the four-week road trip, the Road Scholars will attend community events, conduct random acts of kindness and sampling, host customer appreciation events at Save-A-Lot stores, and share tips for affordable, easy road trip snacks, and breakfast and lunch ideas.
As part of the national search for this year’s Road Scholars, teams of two are invited to submit their resumes, writing samples and a 90-second-or-less audition video explaining why they deserve this unique internship. Videos will be evaluated based on originality, creativity and poise, as well as applicants’ ability to create social media buzz for their videos. Candidates must be college graduates or enrolled in an accredited college and have strong communications, social media and interpersonal skills.
This year’s Fuel Your Family Road Trip route will include stops in Florida; Georgia; South Carolina; North Carolina; Virginia; Washington, D.C.; Maryland; and New York.
The experiential program was created to give consumers the opportunity to personally connect with the Save-A-Lot brand and raise awareness of Save-A-Lot as a destination.
In 2011, the road trip team of Abby Tinberg and Bob Ringer visited 10 U.S. cities.
Barilla rolls out microwaveable meals
BANNOCKBURN, Ill. — A new line of shelf-stable microwaveable meals has arrived from Barilla.
The pasta brand has introduced five varieties of microwaveable meals, including mezze penne with traditional marinara sauce, mezze penne with tomato and basil Sauce, mezze penne with spicy marinara sauce, whole grain fusilli with vegetable marinara sauce and whole grain mezze penne with tomato and basil sauce. The meals are made with 100% natural ingredients and no preservatives and provide between 10 g and 11 g of protein.
Barilla microwaveable meals carry a suggested retail price of $3.29 per 9-oz. package and available in Albertsons, Giant Foods, Jewel-Osco, Kroger, Publix, Safeway, Stop & Shop, Target and Walmart.
Analyses demonstrate efficacy of Symlin in Type 1, Type 2 diabetes patients
PHILADELPHIA — When one of Amylin Pharmaceuticals’ diabetes drugs is used with mealtime insulin, both Type 1 and Type 2 diabetes patients maintain blood sugar in the normal glucose range on a daily basis, according to two analyses presented at the 72nd Scientific Sessions of the American Diabetes Association.
The analyses, which are based off of previously completed clinical studies, aimed to demonstrate how patients taking Symlin (pramlintide acetate) injection treatment (in conjunction with insulin) achieved a greater proportion of blood-glucose measurements in the normal range. In both analyses, researchers looked at each patient’s self-monitored blood-glucose readings before and after breakfast, lunch and dinner, and determined what proportion of those readings fell within the normal range, according to the targets set by American Diabetes Association and the American Association of Clinical Endocrinologists. Normal glucose range was defined as 70-130 mg/dL pre-meal and 70-180 mg/dL post-meal using ADA guidelines, and 70 to less than 110 mg/dL pre-meal and 70 to less than 140 mg/dL post-meal using AACE guidelines.
In the clinical data analysis of 138 patients with Type 2 diabetes, the proportion of measurements in the normal range for Symlin-treated patients increased from 37.2% at baseline to 54.6% at six months, according to ADA guidelines, and from 19.7% to 28.4%, according to AACE guidelines. Similar improvements also were seen in analyses of two studies of patients with Type 1 diabetes. In the first analysis of 218 patients from an open-label clinical practice study, the percent of measurements in the normal range increased from 44.3% at baseline to 52.5% (ADA) at six months and from 27.7% to 32.7% (AACE). In the second analysis of 248 patients from a 29-week, placebo-controlled study, measurements in the normal range based on ADA criteria increased from 37.3% to 43.9% for 115 Symlin-treated patients, compared with an increase from 38.2%to 40.9% in 133 patients receiving placebo.
"These results showed that Symlin, when used with mealtime insulin, helped patients maintain their blood sugar in the normal glucose range on a daily basis," said David Maggs, VP medical research and development at Amylin. "These data provide a ‘real-world’ analysis into the management of daily glucose levels as many patients, whether they have Type 1 or Type 2 diabetes, struggle to maintain target blood glucose levels despite treatment with mealtime insulin."